Clinical manifestations in female carriers of mucopolysaccharidosis type II: a Spanish cross-sectional study
- PMID: 23800320
- PMCID: PMC3697996
- DOI: 10.1186/1750-1172-8-92
Clinical manifestations in female carriers of mucopolysaccharidosis type II: a Spanish cross-sectional study
Abstract
Background: Mucopolysaccharidosis type II (MPS II) is an inherited X-linked disease associated with a deficiency in the enzyme iduronate 2-sulfatase due to iduronate 2-sulfatase gene (IDS) mutations. Recent studies in MPS II carriers did not find clinical involvement, but these were mainly performed by anamnesis and patients' self-reported description of signs and symptoms. So although it is rare in heterozygous carriers, investigations in other types of inherited X-linked disorders suggest that some clinical manifestations may be a possibility. The aim of this study was to evaluate the clinical pattern in female carriers of MPS II and to determine whether clinical symptoms were associated with the X-chromosome inactivation (XCI) pattern and age.
Methods: Female carriers of MPS II were genetically identified by molecular analysis of IDS. The clinical evaluation protocol included pedigree analysis, a comprehensive anamnesis, complete physical examination, ophthalmological evaluation, brain-evoked auditory response, electrocardiogram, echocardiogram, pulmonary function tests, abdominal sonogram, skeletal survey, neurophysiological studies, blood cell counts and biochemistry, urine glycosaminoglycan (GAGs) quantification, karyotype and pattern of XCI.
Results: Ten women were included in the study. The mean age of the participants was 40.2 ± 13.1 years. Six carriers presented a skewed XCI pattern, 3 of whom (aged 38, 42 and 52 years) had increased levels of GAGs in the urine and showed typical MPS II clinical manifestations, such as skeletal anomalies, liver abnormalities, carpal tunnel syndrome, recurrent ear infection, hypoacusia and more frequent severe odontological problems without coarse facial features.
Conclusions: This is the first study performing a comprehensive evaluation of heterozygous MPS II carriers. Our results provide evidence of possible progressive, age-dependent, mild clinical manifestations in MPS II female carriers with a skewed XCI pattern, most likely affecting the normal allele. Further comparative studies with systematized clinical examinations in larger age-stratified populations of MPS II female carriers are required.
Figures
Similar articles
-
Mucopolysaccharidosis type II in a female patient with a reciprocal X;9 translocation and skewed X chromosome inactivation.Am J Med Genet A. 2014 Oct;164A(10):2627-32. doi: 10.1002/ajmg.a.36667. Epub 2014 Jul 8. Am J Med Genet A. 2014. PMID: 25044788
-
Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase.Mol Genet Metab. 2016 Jul;118(3):190-197. doi: 10.1016/j.ymgme.2016.05.003. Epub 2016 May 7. Mol Genet Metab. 2016. PMID: 27246110
-
Female Hunter syndrome caused by a single mutation and familial XCI skewing: implications for other X-linked disorders.Clin Genet. 2011 Nov;80(5):459-65. doi: 10.1111/j.1399-0004.2010.01574.x. Epub 2010 Nov 10. Clin Genet. 2011. PMID: 21062272
-
Mucopolysaccharidosis type II: skeletal-muscle system involvement.J Pediatr Orthop B. 2010 Jul;19(4):313-7. doi: 10.1097/BPB.0b013e3283317b7a. J Pediatr Orthop B. 2010. PMID: 20354449 Review.
-
Differences in MPS I and MPS II Disease Manifestations.Int J Mol Sci. 2021 Jul 23;22(15):7888. doi: 10.3390/ijms22157888. Int J Mol Sci. 2021. PMID: 34360653 Free PMC article. Review.
Cited by
-
A 1-year and 4-month-old child with mucopolysaccharidoses type II: A clinical case report from Ethiopia.Clin Case Rep. 2021 Nov 22;9(11):e05122. doi: 10.1002/ccr3.5122. eCollection 2021 Nov. Clin Case Rep. 2021. PMID: 34849229 Free PMC article.
-
A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management.Intractable Rare Dis Res. 2020 Feb;9(1):1-9. doi: 10.5582/irdr.2020.01011. Intractable Rare Dis Res. 2020. PMID: 32201668 Free PMC article. Review.
-
Epidemiology of mucopolysaccharidoses.Mol Genet Metab. 2017 Jul;121(3):227-240. doi: 10.1016/j.ymgme.2017.05.016. Epub 2017 May 26. Mol Genet Metab. 2017. PMID: 28595941 Free PMC article.
-
Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions.Diagnostics (Basel). 2020 Aug 4;10(8):554. doi: 10.3390/diagnostics10080554. Diagnostics (Basel). 2020. PMID: 32759694 Free PMC article. Review.
-
Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment.Int J Mol Sci. 2020 Feb 13;21(4):1258. doi: 10.3390/ijms21041258. Int J Mol Sci. 2020. PMID: 32070051 Free PMC article. Review.
References
-
- Scarpa M, Almássy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, Guffon N, Guillén-Navarro E, Hensman P, Jones S, Kamin W, Kampmann C, Lampe C, Lavery CA, Teles EL, Link B, Lund AM, Malm G, Pitz S, Rothera M, Stewart C, Tylki-Szymańska A, van der Ploeg A, Walker R, Zeman J, Wraith JE. Hunter Syndrome Europena Expert Council Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011;6:72. doi: 10.1186/1750-1172-6-72. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical